Nektar Therapeutics (NASDAQ:NKTR) price closed higher on Monday, June 30, and jumping 0.31% above its previous close.
A look at the daily price movement shows that the last close reads $25.76, with intraday deals fluctuated between $25.03 and $27.99. The company’s 5Y monthly beta was ticking 0.556. Taking into account the 52-week price action we note that the stock hit a 52-week high of $37.38 and 52-week low of $6.48. The stock added 132.98% on its value in the past month.
Nektar Therapeutics, which has a market valuation of $320.59 million, is expected to release its quarterly earnings report on 2025-May-08.
Technical indicators in stocks provide crucial insights into market trends, guiding investors with precise entry and exit points based on price movements for informed decision-making.On the technical perspective front, indicators give NKTR a short term outlook of 50% Buy on average. Looking at the stock’s medium term indicators we note that it is averaging as a Hold, while an average of long term indicators are currently assigning the stock as 50% Buy.
Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Specifically, 3 analysts have assigned NKTR a recommendation rating as follows: 1 rate it as a Hold; 2 advise Buy while 0 analyst(s) assign an Overweight rating. 0 analyst(s) have tagged the Nektar Therapeutics (NKTR) stock as Underweight, with 0 recommending Sell. In general, analysts have rated the stock Buy, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares.
The overview shows that NKTR’s price is at present 83.90% off the SMA20 and 118.07% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 72.93, with weekly volatility standing at 35.92%. The indicator jumps to 20.12% when calculated based on the past 30 days. Nektar Therapeutics (NASDAQ:NKTR)’s beta value is holding at 0.89. Considering analysts have assigned the stock a price target range of $6-$24 as the low and high respectively, we find the trailing 12-month average consensus price target to be $18.5. Based on this estimate, we see that current price is roughly 76.78% off the estimated low and 7.12% off the forecast high. Investors will no doubt be excited to see the share price rise to $18.5, which is the median consensus price, and at that level NKTR would be 28.41% from current price.
An analysis of the Nektar Therapeutics (NASDAQ:NKTR) stock in terms of its daily trading volume indicates that the 3-month average is 1.43 million. However, this figure increases on the past 10-day timeline to an average of 8.12 million.
Current records show that the company has 12.41M in outstanding shares. The insiders’ percentage holdings are 3.59% of outstanding shares. The stats also highlight that short interest as of 2025-06-13, stood at 0.6 million shares, which puts the short ratio at the time at 2.36. From this we can glean that short interest is 495.00 of company’s current outstanding shares. Notably, we see that shares short in June fall slightly given the previous month’s figure stood at 0.71 million. But the 58.77% upside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.
